在夜晚的新冠疫情之下。
Under COVID of the night.
作者信息
Sekeres Mikkael A
机构信息
Cleveland Clinic.
出版信息
Blood. 2020 Dec 17;136(25):2844-2845. doi: 10.1182/blood.2020009377.
Abstract
In this issue of , Vijenthira and colleagues report that patients who have 2 life-threatening conditions, a hematologic malignancy and infection with the virulent microbe COVID-19, face a risk of dying that is ∼1 in 3.
摘要
在本期杂志中，维金蒂拉及其同事报告称，患有两种危及生命疾病（血液系统恶性肿瘤和感染烈性微生物新冠病毒）的患者面临着约三分之一的死亡风险。
相似文献
1
Under COVID of the night.在夜晚的新冠疫情之下。
Blood. 2020 Dec 17;136(25):2844-2845. doi: 10.1182/blood.2020009377.
2
Night-shift work is associated with increased susceptibility to SARS-CoV-2 infection.夜班工作与增加对 SARS-CoV-2 感染的易感性有关。
Chronobiol Int. 2022 Aug;39(8):1100-1109. doi: 10.1080/07420528.2022.2069031. Epub 2022 May 2.
3
Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic malignancies.在血液系统恶性肿瘤患者中，感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变异株的结果与感染先前变异株相似。
Ann Hematol. 2022 Aug;101(8):1877-1878. doi: 10.1007/s00277-022-04833-8. Epub 2022 Apr 7.
4
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.血液系统恶性肿瘤患者对SARS-CoV-2疫苗的抗体反应。
Cancer Cell. 2021 Aug 9;39(8):1031-1033. doi: 10.1016/j.ccell.2021.07.012. Epub 2021 Jul 22.
5
Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 M for pharmacological interventions in COVID-19 pandemic.昼夜节律钟调节小分子重新用作严重急性呼吸综合征冠状病毒2（SARS-CoV-2）M蛋白的抑制剂，用于2019冠状病毒病大流行的药物干预。
Chronobiol Int. 2021 Jul;38(7):971-985. doi: 10.1080/07420528.2021.1903027. Epub 2021 Apr 6.
6
Hematological Aspects of COVID-19.新型冠状病毒肺炎的血液学特征
Acta Haematol. 2022;145(3):233-234. doi: 10.1159/000524047. Epub 2022 Mar 21.
7
Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?血液系统恶性肿瘤患者对新冠疫苗的细胞反应：无反应者的新希望？
Leuk Lymphoma. 2022 Mar;63(3):743-746. doi: 10.1080/10428194.2021.1998485. Epub 2021 Oct 28.
8
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report.血液系统恶性肿瘤患者感染奥密克戎SARS-CoV-2变异株的结局：一项EPICOVIDEHA调查报告
Am J Hematol. 2022 Aug;97(8):E312-E317. doi: 10.1002/ajh.26626. Epub 2022 Jun 28.
9
Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders.血液系统疾病患者中新型冠状病毒2型感染的严重程度和90天生存率
Acta Oncol. 2022 Apr;61(4):500-504. doi: 10.1080/0284186X.2022.2026464. Epub 2022 Jan 17.
10
引用本文的文献
1
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.淋巴瘤合并 COVID-19 患者的预后模型：一项多中心队列研究。
Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691.
本文引用的文献
1
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.血液系统恶性肿瘤合并 COVID-19 患者的结局：对 3377 例患者的系统评价和荟萃分析。
Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824.
2
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19.SARS-CoV-2 病毒载量可预测 COVID-19 住院患者的死亡率，无论其是否患有癌症。
Cancer Cell. 2020 Nov 9;38(5):661-671.e2. doi: 10.1016/j.ccell.2020.09.007. Epub 2020 Sep 15.
3
The association of race and COVID-19 mortality.种族与新冠病毒疾病死亡率之间的关联。
EClinicalMedicine. 2020 Aug;25:100455. doi: 10.1016/j.eclinm.2020.100455. Epub 2020 Jul 15.
4
The Age-Related Risk of Severe Outcomes Due to COVID-19 Infection: A Rapid Review, Meta-Analysis, and Meta-Regression.与 COVID-19 感染相关的严重结局的年龄相关风险：快速综述、荟萃分析和荟萃回归。
Int J Environ Res Public Health. 2020 Aug 17;17(16):5974. doi: 10.3390/ijerph17165974.
5
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.比较 SARS-CoV-2 与 SARS-CoV 和流感大流行。
Lancet Infect Dis. 2020 Sep;20(9):e238-e244. doi: 10.1016/S1473-3099(20)30484-9. Epub 2020 Jul 3.
Zotero 插件